BR0014859A - Derivados de benzodiazepina - Google Patents

Derivados de benzodiazepina

Info

Publication number
BR0014859A
BR0014859A BR0014859-8A BR0014859A BR0014859A BR 0014859 A BR0014859 A BR 0014859A BR 0014859 A BR0014859 A BR 0014859A BR 0014859 A BR0014859 A BR 0014859A
Authority
BR
Brazil
Prior art keywords
halo
lower alkyl
halogen
optionally substituted
lower alkoxy
Prior art date
Application number
BR0014859-8A
Other languages
English (en)
Inventor
Geo Adam
Alexander Alanine
Erwin Goetschi
Vicent Mutel
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0014859A publication Critical patent/BR0014859A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE BENZODIAZEPINA". A presente invenção refere-se a compostos da fórmula geral (I) em que X é uma ligação simples ou um grupo etinedila, em que, no caso de X ser uma ligação simples, R^ 1^ é halogênio ou fenila que é opcionalmente substituída com halogênio, alquila inferior, halo alquila inferior, alcóxi inferior, halo alcóxi inferior, ou ciano; no caso de X ser um grupo etinedila, R^ 1^ é fenila, opcionalmente substituída com halogênio, alquila inferior, halo alquila inferior, cicloalquila inferior, alcóxi inferior ou halo alcóxi inferior; R^ 3^ é uma arila ou heteroarila de 5 ou 6 membros que é opcionalmente substituída. Os compostos de acordo com a invenção podem ser usados para tratar ou prevenir distúrbios neurológicos agudos e/ou crónicos incluindo psicose, esquizofrenia, doença de Alzheimer, distúrbios cognitivos e déficits de memória.
BR0014859-8A 1999-10-15 2000-09-29 Derivados de benzodiazepina BR0014859A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99120520 1999-10-15
PCT/EP2000/009553 WO2001029011A2 (en) 1999-10-15 2000-09-29 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
BR0014859A true BR0014859A (pt) 2002-07-16

Family

ID=8239207

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014859-8A BR0014859A (pt) 1999-10-15 2000-09-29 Derivados de benzodiazepina

Country Status (35)

Country Link
US (1) US6407094B1 (pt)
EP (1) EP1224174B1 (pt)
JP (1) JP3857138B2 (pt)
KR (1) KR100480320B1 (pt)
CN (1) CN1195522C (pt)
AR (1) AR026029A1 (pt)
AT (1) ATE250039T1 (pt)
AU (1) AU774451B2 (pt)
BR (1) BR0014859A (pt)
CA (1) CA2386974C (pt)
CO (1) CO5261604A1 (pt)
CZ (1) CZ20021653A3 (pt)
DE (1) DE60005386T2 (pt)
DK (1) DK1224174T3 (pt)
EG (1) EG24079A (pt)
ES (1) ES2204704T3 (pt)
GC (1) GC0000263A (pt)
HK (1) HK1051038A1 (pt)
HR (1) HRP20020259A2 (pt)
HU (1) HUP0203142A3 (pt)
IL (2) IL148816A0 (pt)
JO (1) JO2262B1 (pt)
MA (1) MA26831A1 (pt)
MY (1) MY125540A (pt)
NO (1) NO327817B1 (pt)
NZ (1) NZ517999A (pt)
PE (1) PE20010681A1 (pt)
PL (1) PL357418A1 (pt)
PT (1) PT1224174E (pt)
RU (1) RU2259360C2 (pt)
SI (1) SI1224174T1 (pt)
TR (1) TR200201023T2 (pt)
WO (1) WO2001029011A2 (pt)
YU (1) YU26202A (pt)
ZA (1) ZA200202544B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1199954C (zh) 1999-10-15 2005-05-04 弗·哈夫曼-拉罗切有限公司 苯并二氮杂䓬衍生物
HUP0400991A3 (en) * 2001-04-12 2009-06-29 Hoffmann La Roche Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i, process for their preparation and pharmaceutical compositions containing them
CZ20033003A3 (cs) 2001-04-12 2004-05-12 F@Áhoffmann@Laárocheáag Dihydrobenzo [b][�Ź@]diazepin@onové deriváty jako MGLUR@ antagonisty II
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6949542B2 (en) 2002-02-06 2005-09-27 Hoffman-La Roche Inc. Dihydro-benzo[b][1,4]diazepin-2-one derivatives
US8354447B2 (en) * 2002-09-10 2013-01-15 The Scripps Research Institute mGLU receptors antagonists for treating disorders associated with mGLU receptors including addiction and depression
ATE510174T1 (de) 2003-05-21 2011-06-15 Alexza Pharmaceuticals Inc Schlag gezündete unabhängige heizeinheit
BRPI0412919A (pt) * 2003-07-25 2006-09-26 Hoffmann La Roche combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos
FR2862969A1 (fr) 2003-11-28 2005-06-03 Oreal Procede de preparation de derives paraphenylenediamine a groupement pyrrolidinyle, substitue par un radical azote, et composes intermediaires
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7459563B2 (en) 2004-11-05 2008-12-02 Hoffmann-La Roche Inc. Process for the preparation of isonicotinic acid derivatives
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
EP2137167B1 (en) * 2007-04-19 2011-08-10 F. Hoffmann-La Roche AG Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives
TW200927731A (en) * 2007-09-14 2009-07-01 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
EA019085B1 (ru) 2007-09-14 2014-01-30 Янссен Фармасьютикалз, Инк. 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
RU2488591C2 (ru) * 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Аналоги азацитидина и их применение
JP5433582B2 (ja) * 2007-11-14 2014-03-05 ジャンセン ファーマシューティカルズ， インコーポレイテッド． イミダゾ［１，２−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
JP5634506B2 (ja) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN101891706B (zh) * 2010-04-09 2013-05-29 复旦大学 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途
EP2599775A4 (en) 2010-07-29 2014-04-30 Taisho Pharmaceutical Co Ltd ETHINYLPYRAZOLDERIVAT
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP2012153674A (ja) * 2011-01-28 2012-08-16 Astellas Pharma Inc ジ（アリールアミノ）アリール化合物の製造方法及びその合成中間体
CN104736140A (zh) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3096790T (lt) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
US9895324B2 (en) 2014-03-26 2018-02-20 University Of Kentucky Research Foundation Halogenated diarylacetylenes and methods of treating cancer
EP3134089A2 (en) 2014-04-23 2017-03-01 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of intellectual disabilities
CA2950952C (en) 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
CN106243050B (zh) * 2016-08-10 2019-09-06 安徽恒星制药有限公司 一种适合工业化生产氯巴占的方法
CN109836356B (zh) * 2017-11-24 2022-03-08 沈阳化工研究院有限公司 一种芳甲醚衍生物及其应用
RU2702358C1 (ru) * 2019-06-04 2019-10-08 Федеральное государственное бюджетное научное учреждение Уфимский федеральный исследовательский центр Российской академии наук Способ получения 2,2,4-триалкил-2,3-дигидро-1Н-1,5-бензодиазепинов
CN114349779B (zh) * 2021-12-29 2023-09-26 智仑超纯环氧树脂(西安)有限公司 一种改性二氧化硅颗粒除氯剂及其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11509847A (ja) * 1995-07-31 1999-08-31 ノボ ノルディスク アクティーゼルスカブ ヘテロ環式化合物、それらの調製及び使用
CN1158264C (zh) * 1997-11-21 2004-07-21 Nps药物有限公司 用于治疗中枢神经***疾病的代谢性谷氨酸受体拮抗剂

Also Published As

Publication number Publication date
CN1379765A (zh) 2002-11-13
AR026029A1 (es) 2002-12-26
DE60005386D1 (de) 2003-10-23
KR20020038954A (ko) 2002-05-24
MY125540A (en) 2006-08-30
IL148816A0 (en) 2002-09-12
WO2001029011A2 (en) 2001-04-26
SI1224174T1 (en) 2003-12-31
CN1195522C (zh) 2005-04-06
HUP0203142A3 (en) 2003-03-28
EP1224174B1 (en) 2003-09-17
US6407094B1 (en) 2002-06-18
NO327817B1 (no) 2009-09-28
MA26831A1 (fr) 2004-12-20
JP3857138B2 (ja) 2006-12-13
PT1224174E (pt) 2004-01-30
YU26202A (sh) 2004-12-31
PL357418A1 (en) 2004-07-26
TR200201023T2 (tr) 2002-09-23
NO20021690L (no) 2002-04-10
NO20021690D0 (no) 2002-04-10
CA2386974C (en) 2009-10-13
CA2386974A1 (en) 2001-04-26
AU774451B2 (en) 2004-06-24
NZ517999A (en) 2004-07-30
CZ20021653A3 (cs) 2002-08-14
KR100480320B1 (ko) 2005-04-07
AU7910200A (en) 2001-04-30
IL148816A (en) 2006-10-31
CO5261604A1 (es) 2003-03-31
JO2262B1 (en) 2004-10-07
ATE250039T1 (de) 2003-10-15
JP2003512359A (ja) 2003-04-02
RU2259360C2 (ru) 2005-08-27
EG24079A (en) 2008-05-11
DK1224174T3 (da) 2004-01-26
DE60005386T2 (de) 2004-06-24
EP1224174A2 (en) 2002-07-24
PE20010681A1 (es) 2001-06-28
HK1051038A1 (en) 2003-07-18
GC0000263A (en) 2006-11-01
HRP20020259A2 (en) 2004-04-30
HUP0203142A2 (hu) 2003-02-28
WO2001029011A3 (en) 2001-11-08
ZA200202544B (en) 2003-09-23
ES2204704T3 (es) 2004-05-01

Similar Documents

Publication Publication Date Title
BR0014859A (pt) Derivados de benzodiazepina
BR0014761A (pt) Derivados de benzodiazepina
BR0314059A (pt) Compostos heterocìclicos
PE86599A1 (es) Inhibidores de la farnesil proteina transferasa
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BR9806752A (pt) Ftalazinonas.
BR0011770A (pt) Composto, e, composição farmacêutica
ATE432261T1 (de) Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
BR0209149A (pt) Ftalazinonas
BR0206495A (pt) Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
DE69021639D1 (de) Disäuren von Diarylstyrylchinolin.
ATE93231T1 (de) In 2-stellung substituierte cumaranderivate.
DE69418789D1 (de) 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren
BRPI0414573A (pt) 7-amino alquilidenil-quinolonas e naftiridonas heterocìclicas
BR0116900A (pt) Sistema estabilizador para a estabilização de polìmeros contendo halogênio
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
DE50201565D1 (de) 2-thio-subsituierte imidazolderivative und ihre verwendung in der pharmazie
BR0111915A (pt) 5-aminoalquilpirazolo[4,3-d]pirimidinas
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
DK0806413T3 (da) 2-substituerede viatmin D3-derivater
BR0113452A (pt) Derivados de 4-, 5-, 6- e 7- indol úteis para o tratamento de distúrbios do snc, o composto; sua composição farmacêutica e uso do mesmo
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla
EA200400770A1 (ru) Производные 5-(пиридин-3-ил)-1-азабицикло[3.2.1]октана, их получение и применение в терапии
BR0112092A (pt) 2-aminoalquiltieno[2,3-d]pirimidinas

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 43/00

Ipc: C07D 243/12 (2009.01), A61K 31/551 (2009.01), A61P

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements